The initiation of coverage on Abivax by Guggenheim and Piper Sandler with bullish ratings directly impacts the stock's value by increasing investor confidence and potentially attracting more investment. Analyst ratings, especially from reputable firms, can significantly influence market perception and stock prices in the short term.